Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCIIhigh dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCIIhigh dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these results have been obtained in young mice, and it is still not known if this mechanisms are preserved in aged animals [174].”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [174]
Citations
Cites
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., Gherardi, R. K., & Chazaud, B. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070075 · Cited by 2,002
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Jung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells
Auffray, C., Sieweke, M. H., & Geissmann, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132557 · Cited by 1,655
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Self-citationFirst Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationA Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752 · cited 2×
“Recently, the RTS,S vaccine was shown to confer protection of 30–47% against uncomplicated and severe malaria in young African children and infants, respectively (17, 18).”
BackgroundHEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713
Cited by
Items 101–200 of 267
AboulFotouh, K., Xu, H., Moon, C., Williams, R. O., & Cui, Z. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121825 · Cited by 34
Identification and Characterization of CD4 + T Cell Epitopes after Shingrix Vaccination
Voic, H., de Vries, R. D., Sidney, J., Rubiro, P., Moore, E. C., Phillips, E. J., Mallal, S. A., Schwan, B., Weiskopf, D., Sette, A., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01641-20 · Cited by 31
“It has been previously shown that the ASB01 adjuvant, in general, induces a mixed 191 Th1/Th2 T cell phenotype (16).”
Fougeron, D., Maele, L. V., Songhet, P., Cayet, D., Hot, D., van Rooijen, N., Mollenkopf, H., Hardt, W., Benecke, A., & Sirard, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.022 · Cited by 39
Commonly Used Adjuvant Human Vaccines: Advantages and Side Effects
Villarreal, R., & Casale, T. B. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.04.045 · Cited by 31
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
Bell, M. R., & Kutzler, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114175 · Cited by 29
Kim, S. K., Yun, C., & Han, S. H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00435 · Cited by 29
“Given the fact that enhanced T cell responses have previously been observed with many existing adjuvants, including MPLA, saponin, and CT (31, 32), this enhancement appeared to be mediated through DC activation.”
BackgroundA novelin silicoframework to improve MHC-I epitopes and break the tolerance to melanoma
Capasso, C., Magarkar, A., Cervera-Carrascón, V., Fusciello, M., Feola, S., Müller, M. J., Garofalo, M., Kuryk, Ł., Tähtinen, S., Pastore, L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1319028 · Cited by 29
“The CD8C T-cells of C57BL/6-Tg(TcraTcrb)1100Mjb/Crl (OTI) mice (Charles River) have a T-cell receptor specific for the OVA-derived class I epitope SIINFEKL.(39) Spleens were collected from OT-I mice and were gently disrupted through 70 mM cell strainers and single cell suspensions were frozen in 10% DMSO at ¡80 C.”
MethodInfluentialInter-Pathogen Peptide Sharing and the Original Antigenic Sin: Solving a Paradox
Kanduc, D., & Shoenfeld, Y. (2018) · The Open Immunology Journal · doi:10.2174/1874226201808010016 · Cited by 28
Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys
Collignon, C., Bol, V., Chalon, A., Surendran, N., Morel, S., van den Berg, R. A., Capone, S., Bechtold, V., & Temmerman, S. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579872 · Cited by 29
“Tissue samples dissected from muscles and dLN were individually homogenized, and cytokine levels were measured in tissue-homogenate supernatants as described previously (27, 28).”
MethodSelf-citationAdvancing Adjuvants for Mycobacterium tuberculosis Therapeutics
Enriquez, A. B., Izzo, A. A., Miller, S. M., Stewart, E. L., Mahon, R. N., Frank, D. J., Evans, J. T., Rengarajan, J., & Triccas, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740117 · Cited by 29
“DCs express high levels of TLR4 and are highly responsive to MPL, driving downstream antigen-specific T cell differentiation (11, 20).”
BackgroundNano alum: A new solution to the new challenge
Lü, Y., & Liu, G. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060667 · Cited by 28
Alving, C. R., Rao, M., & Matyas, G. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102524 · Cited by 30
“The fate of AS01 particles after intramuscular injection in mice has been reported previously (47), and studies on the effects of particle size on tissue distribution of polydisperse ALFQ vs.”
BackgroundFunctional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine
Bechtold, V., Smolen, K. K., Burny, W., Angelis, S. P. D., Delandre, S., Essaghir, A., Marchant, A., N'Dour, C. T., Taton, M., der Most, R. G. V., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl3381 · Cited by 28
“O - desacyl-4 ′ - monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) ligand, and QS-21] ( 2 , 8 – 11 ) may be underpinned by the adjuvant’s ability to trigger early inflammatory signals and recruit activated monocytes and DCs to the draining lymph node ( 12 , 13 ).”
BackgroundSelf-citationWang, Y., Qi, J., Cao, H., & Liu, C. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00261-y · Cited by 26
Development of thermostable vaccine adjuvants
Qi, Y., & Fox, C. B. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1902314 · Cited by 25
Studies with herpes zoster vaccines in immune compromised patients
Levin, M. J., Bresnitz, E. A., Popmihajlov, Z., Weinberg, A., Liaw, K., Willis, E. D., & Curtis, J. R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1395703 · Cited by 26
“These components work synergistically to enhance the number of VZV-specific T cells [107].”
BackgroundThe challenges of a circumsporozoite protein-based malaria vaccine
Chatterjee, D., & Cockburn, I. A. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1874924 · Cited by 30
“(reviewed in depth [57]) can induce a rapid transient response at injection site and draining lymph node, including an influx of CD4 T cells [58], neutrophils and monocytes [59] as well as type II interferon signaling at the injection site [60].”
BackgroundSTING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy
Jia, L., Yang, Q., Li, X., Liu, H., He, Z., & Wang, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123294 · Cited by 25
Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine
Levin, M. J., & Weinberg, A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz770 · Cited by 27
Adjuvants: friends in vaccine formulations against infectious diseases
Manríquez, G. G. G., & Tuero, I. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1934354 · Cited by 25
Doss-Gollin, S., Thomas, S., Brook, B., Abedi, K., Lebas, C., Auderset, F., Rodriguez, Y. L., Sánchez‐Schmitz, G., Dowling, D. J., Levy, O., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00759-y · Cited by 26
“The mechanistic and synergistic action of MPL + QS-21 liposomal co-formulation that we describe is comparable to the MOA of AS-01 previously described 26 – 28 .”
ResultChemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Lv, X., Martin, J., Hoover, H. S., Joshi, B. P., Wilkens, M. K., Ullisch, D. A., Leibold, T., Juchum, J., Revadkar, S., Kalinovska, B., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109006 · Cited by 26
“38,39 This cytokine profile can be further biased toward T H 1 response priming upon combination with a TLR4 agonist.”
BackgroundPoly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine
Nguyen, Q. T., Kwak, C., Lee, W. S., Kim, J., Jeong, J., Sung, M., Yang, J., & Poo, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01604 · Cited by 24
“consistent with previous findings obtained with the MPL-based adjuvants, AS04 and AS01 (37, 38).”
BackgroundResultDeciphering host immunity to malaria using systems immunology
Loiseau, C., Cooper, M. M., & Doolan, D. L. (2019) · Immunological Reviews · doi:10.1111/imr.12814 · Cited by 24
Liposome Formulations as Adjuvants for Vaccines
Rao, M., Peachman, K. K., & Alving, C. R. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_227 · Cited by 26
Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation
Veld, L. G. M. H. I. ‘., Ho, N. I., Wassink, M., den Brok, M. H., & Adema, G. J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04253-x · Cited by 23
Adjuvants: tailoring humoral immune responses
McElrath, M. J. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000365 · Cited by 21
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Innate immune cell activation by adjuvant AS01 in human lymph node explants is age independent
Stylianou, V. V., Bertram, K. M., Vo, V. A., Dunn, E. B., Baharlou, H., Terre, D. D., Elhindi, J., Elder, E. E., French, J. R., Meybodi, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174144 · Cited by 27
“QS-21 has been shown to activate the NLRP3 inflammasome, resulting in IL-1 β and IL-18 production (10, 18), although in response to AS01, IL-1 β has only been detected at very low levels in mice (8), and whether AS01 activates the inflammasome is still unclear.”
InfluentialSelf-citationBouzya, B., Rouxel, R. N., Sacconnay, L., Mascolo, R., Nols, L., Quique, S., François, L., Atas, A., Warter, L., Dezutter, N., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00729-4 · Cited by 22
“Due to diverging HLA expression and antigen presentation, the murine CD8 + T cell responses were not surprising and also seen for other proteins 29,55 , though this effect may be antigen-dependent given the inconsistent responses seen for VZV gE in mice 41,49 .”
Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis
Liu, W., Zhu, M., Yu, Z., Yin, D., Lu, F., Pu, Y., Zhao, C., He, C., & Cao, L. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.018 · Cited by 22
Carbohydrate-based vaccine adjuvants – discovery and development
Hu, J., Qiu, L., Wang, X., Zou, X., Lu, M., & Yin, J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1067198 · Cited by 20
“AS01 has been applied in both non-clinical and clinical (Phase I -- III) vaccines research including the malaria vaccine [29,30] and the varicella-zoster virus subunit vaccine [31].”
MethodLosa, L., Antonazzo, I. C., Martino, G. D., Mazzaglia, G., Tafuri, S., Mantovani, L. G., & Ferrara, P. (2024) · Vaccines · doi:10.3390/vaccines12050527 · Cited by 22
Pejoski, D., de Rham, C., Martinez-Murillo, P., Santoro, F., Auderset, F., Medaglini, D., Pozzi, G., Vono, M., Lambert, P., Huttner, A., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0179-4 · Cited by 21
Aguilar‐Gurrieri, C., Barajas, A., Rovirosa, C., Ortiz, R., Urrea, V., de la Iglesia, N., Clotet, B., Blanco, J., & Carrillo, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03409-3 · Cited by 20
“Remarkably, the detection of H2Kb/SIINFEKL complexes in transfected B16-F10 cells showed no differences among constructs (Fig.”
BackgroundInfluentialSegal, L. M., Morelle, D., Blee, M., Moore, E., Damsten, M. C., Liu, K. C., Destexhe, É., & Garçon, N. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.12.017 · Cited by 18
“The observed transient effects and the effects in the lymph nodes are in line with the recently described AS01 mode of action (Didierlaurent et al., 2014).”
ResultSelf-citationIn Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity
Chikovani, T., & Magen, E. (2025) · Vaccines · doi:10.3390/vaccines13111114 · Cited by 18
“In vaccinology, the choice of adjuvant is paramount and tailored to induce a specific immune response (e.g., Th1 vs. Th2) [85,86].”
TET2 promotes tumor antigen presentation and T cell IFN-γ, which is enhanced by vitamin C
Cheng, M., Chu, A. K. Y., Li, Z., Yang, S., Smith, M. D., Zhang, Q., Brown, N. G., Marzluff, W. F., Bardeesy, N., Milner, J. J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175098 · Cited by 17
Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses
Saleemi, M. A., Zhang, Y., & Zhang, G. (2024) · Pathogens · doi:10.3390/pathogens13060441 · Cited by 20
“The delivery system for vaccines concentrates on the activation of the immune signal, which can be focused on the antigen formulation [174,175].”
BackgroundInfluentialVeld, L. G. M. H. I. ‘., Cornelissen, L. A. M., van den Bogaard, L., Ansems, M., Ho, N. I., & Adema, G. J. (2025) · npj Vaccines · doi:10.1038/s41541-024-01056-y · Cited by 20
“Radioactive and fl uorescent labeling of SBAs and their corresponding antigens has previously been used to study biodistribution after in vivo injection and to determine the injection route giving the best protective effect of vaccination 36 – 39 .”
He, L., Sun, B., Guo, Y., Yan, K., Liu, D., Zang, Y., Jiang, C., Zhang, Y., & Kong, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108216 · Cited by 19
Highlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
Shen, L., Luo, H., Fan, L., Su, Z., Yu, S., Cao, S., & Wu, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155302 · Cited by 16
Zoster Vaccination in Older Adults: Efficacy and Public Health Implications
McElhaney, J. E., Verschoor, C. P., & Pawelec, G. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz085 · Cited by 16
Maele, L. V., Fougeron, D., Cayet, D., Chalon, A., Piccioli, D., Collignon, C., Sirard, J., & Didierlaurent, A. M. (2019) · European Journal of Immunology · doi:10.1002/eji.201948234 · Cited by 14
Self-citationThe scientific journey of a novel adjuvant (AS37) from bench to bedside
D’Oro, U., & O’Hagan, D. T. (2024) · npj Vaccines · doi:10.1038/s41541-024-00810-6 · Cited by 14
“…research of the kinetics of successful TLRa-based adjuvants in mice had shown a transient innate immune response which peaked within the fi rst 3 days post-injection 31,32 , and the (alum-formulated) TLR7a was later shown to display similar kinetics in NHPs and humans 33,34 , as detailed below.”
BackgroundUnderstanding natural herpes simplex virus immunity to inform next‐generation vaccine design
Sandgren, K. J., Bertram, K. M., & Cunningham, A. L. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.44 · Cited by 18
Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants
Fox, C. B., Carter, D., Kramer, R. M., Beckmann, A. M., & Reed, S. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00006-2 · Cited by 25
In, H. J., Lim, H., Lee, J.-A., Kim, H. J., Kim, J.-W., Hyeon, J.-Y., Yeo, S.-G., Lee, J.-W., Yoo, J. S., Choi, Y. K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178259 · Cited by 14
Reverse development of vaccines against antimicrobial-resistant pathogens
Bagnoli, F., Galgani, I., Vadivelu, V. K., & Phogat, S. K. (2024) · npj Vaccines · doi:10.1038/s41541-024-00858-4 · Cited by 15
Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
Li, B., Siuta, M., Bright, V., Koktysh, D. S., Matlock, B. K., Dumas, M. E., Zhu, M.-Y., Holt, A., Stec, D. F., Deng, S., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s112432 · Cited by 13
Stranahan, L. W., Chaki, S. P., Garcia-Gonzalez, D. G., Khalaf, O. H., & Arenas-Gamboa, Á. M. (2020) · mSphere · doi:10.1128/msphere.00172-20 · Cited by 13
Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation
Smith, C. L., Richardson, B., Rubsamen, M., Cameron, M. J., Cameron, C., & Canaday, D. H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.010 · Cited by 12
Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine
Luo, K., Zavala, F. P., Gordy, J. T., Zhang, H., & Markham, R. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.052 · Cited by 12
“The activity of the AS01 adjuvant, a proprietary formulation of GlaxoSmithKline containing monophosphoryl lipid A and QS-21, has been shown to be associated with the ability of AS01 to increase the number of MHCII dendritic cells at the immunization site and at adjacent lymph nodes [32].”
Giordano, G., Segal, L. M., Prinsen, M. K., Wijnands, M. V. W., Garçon, N., & Destexhe, É. (2016) · Journal of Applied Toxicology · doi:10.1002/jat.3329 · Cited by 13
“The results of the local tolerance assessment with a variant of AS01 containing half the amounts of QS-21 and MPL per 500μl were similar (data not shown).”
BackgroundMethodInfluentialSelf-citationShimizu, T., Kawaguchi, Y., Ando, H., Ishima, Y., & Ishida, T. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00047 · Cited by 13
Pirrotta, P., Silva, F. T. D., Co, M. M., Lecrenier, N., Hervé, C., & Stegmann, J. (2021) · Drug Safety · doi:10.1007/s40264-021-01118-3 · Cited by 14
Introduction to Vaccines and Vaccination
Depelsenaire, A. C. I., Kendall, M. A. F., Young, P. R., & Muller, D. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39981-4.00003-8 · Cited by 13
Garçon, N., Silvano, J., Kuper, C. F., Baudson, N., Gerard, C. M., Forster, R. P., & Segal, L. M. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3167 · Cited by 13
Self-citationFrom bark to bench: innovations in QS-21 adjuvant characterization and manufacturing
Talukdar, P., Winegar, P. H., Hudson, G. A., Astolfi, M. C. T., Inman, J. L., Keasling, J. D., & Mukundan, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677995 · Cited by 15
Dieng, C. C., Ford, C. T., Lerch, A., Donu, D., Huynh, J., Vegesna, K., Guo, J., Janies, D. A., Amoah, L. E., Afrane, Y. A., et al. (2023) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2023.105418 · Cited by 13
Practical Considerations for Next-Generation Adjuvant Development and Translation
Lykins, W. R., & Fox, C. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071850 · Cited by 16
“Adjuvants are also critical in the development of long-term memory cell populations, which in turn can lead to years-long protection [5,6].”
BackgroundBiodistribution of the saponin-based adjuvant Matrix-M™ following intramuscular injection in mice
Carnrot, C., Carow, B., Palm, A.-K. E., Akpinar, E., Helgesson, P.-H., Osterman, I. L., Bringeland, E., Foreman, B. M., Patel, N., Bankefors, J., et al. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1279710 · Cited by 13
Lipid Nanoparticle: Beyond Delivery Vehicle—Unveiling Its Immunological Adjuvant Potential
Amor, N. P., Guo, K., Zhang, S., Xia, J., Yang, Y., & Lin, A. (2025) · The FASEB Journal · doi:10.1096/fj.202500622r · Cited by 13
Zarnegar, B., Carow, B., Eriksson, J., Spennare, E., Öhlund, P., Akpinar, E., Bringeland, E., Osterman, I. L., Lundqvist, L., Antti, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01243-5 · Cited by 17
The Development of the Adjuvant System AS01
Didierlaurent, A. M., Berger, A., Heineman, T. C., Henderickx, V., Silva, F. T. D., Vekemans, J., Voss, G., & Garçon, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00014-1 · Cited by 12
Self-citationVijayan, A., Maele, L. V., Fougeron, D., Cayet, D., & Sirard, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000746 · Cited by 11
Technologies for making new vaccines
Ellis, R. W., Rappuoli, R., & Ahmed, S. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00013-6 · Cited by 14
Immune Responses to Varicella-Zoster Virus Vaccines
Levin, M. J., & Weinberg, A. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_245 · Cited by 13
Fergusson, J. R., Siu, J. H. Y., Gupta, N., Jenkins, E. M., Nee, E., Reinke, S., Ströbel, T., Bhalla, A., Kandage, S. M., Courant, T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115938 · Cited by 13
“23,34,36 S3 and S4.”
InfluentialLi, J., Fu, L., Yang, Y., Wang, G., & Zhao, A. (2022) · Vaccines · doi:10.3390/vaccines10040529 · Cited by 11
Nakayama, T., Sawada, A., & Ito, T. (2022) · Vaccines · doi:10.3390/vaccines10081339 · Cited by 10
“It was considered as a reaction caused by the AS01B adjuvant system, using monophosphoryl lipid A (MPL), Quillaja Saponaria Molina extract QS-21, cholesterol, and dioleoylphosphatidylcholine (DOPC) in the composition of liposomes [13].”
MethodLi, J., Fu, L., Guo, X., Yang, Y., Dong, J., Wang, G., & Zhao, A. (2022) · Vaccines · doi:10.3390/vaccines10122155 · Cited by 11
Rational Design and In Vivo Characterization of Vaccine Adjuvants
Schmidt, S., Pedersen, G. K., & Christensen, D. (2018) · ILAR Journal · doi:10.1093/ilar/ily018 · Cited by 10
“In another study, the liposome-based adjuvant AS01 was shown to induce a transient influx of neutrophils (SSCCD11bLy6G) and monocytes (Ly6CCD11bLy6G) into the muscle injection site.(36) Similar innate cell reactions were observed in rhesus macaques immunized with HIV-1 envelope protein adjuvanted with an aluminum-TLR7…”
BackgroundApplication of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action
Buckley, P. R., Alden, K., Coccia, M., Chalon, A., Collignon, C., Temmerman, S. T., Didierlaurent, A. M., der Most, R. G. V., Timmis, J., Andersen, C. A. F., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02150 · Cited by 11
“IL-12 in the model is hypothesized to be secreted by a pool of DCs, [including monocyte-derived-dendritic-cells (MoDCs)] and activated monocytes.”
BackgroundResultInfluentialSelf-citationTechnologies for Making New Vaccines
Ahmed, S. S., Ellis, R. W., & Rappuoli, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00066-3 · Cited by 12
Johnson, M. J., Crotteau, M., Ghosh, D., Vu, T., Trinity, L., Marcheş, R., Ucar, D., Levin, M. J., & Weinberg, A. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013759 · Cited by 11
“This finding is supported by previous studies showing activation of NK and other innate cells in the draining lymph node of the site of AS01-adjuvanted vaccine inoculation [86,87].”
Belay, W. Y., Kebede, B., Tegegne, B. A., Getachew, M., Abebe, D., Aschale, Y., Belew, H., & Tefera, B. B. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s400155 · Cited by 14
Noh, H. J., Noh, Y., Heo, M. B., Kim, E., Park, S., Kim, Y., Choi, Y. K., & Lim, Y. T. (2016) · Small · doi:10.1002/smll.201602344 · Cited by 9
Segal, L. M., Roger, V., Williams, C., Destexhe, É., & Garçon, N. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.06.003 · Cited by 9
Self-citationUllah, F., Ullah, S., Amin, M., Ullah, W., Ullah, S., & Wang, S. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111557 · Cited by 8
Egorova, E. A., Lamers, G. E. M., Monikh, F. A., Boyle, A. L., Slütter, B., & Kros, A. (2022) · RSC Advances · doi:10.1039/d2ra03027f · Cited by 8
Zhu, G., Yang, Y., & Sun, T. (2022) · Biomaterials Science · doi:10.1039/d2bm00011c · Cited by 8
Luwi, N. M., Ahmad, S., Azlyna, A. S. N., Nordin, N. A., Sarmiento, M. E., Acosta, A., Norazmi, M. N., Uskoković, V., Mohamud, R., & Kadir, R. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.332806 · Cited by 8
Bueno, J. (2017) · Journal of Microbial & Biochemical Technology · doi:10.4172/1948-5948.1000e130 · Cited by 8
“For example, AS01 adjuvant is a mix of liposome, saponin (QS21, derived from Quillaja saponaria) and monophosphoryl lipid A that promote antigen specific cell mediated response as well as antibody responses, and has shown the ability of increase the effectiveness of the RTS,S malaria vaccine [12].”
BackgroundImaging the early fate of mRNA vaccines
Ols, S., & Loré, K. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0399-y · Cited by 8
Li, C., Li, Y., Zhou, B., Li, T., Wei, X., Chen, K., Chen, W., Shi, Z., Dai, X., Zhang, J., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01431-7 · Cited by 11
Mathias, F. A. S., Ostolin, T. L. V. D. P., Reis, L. E. S., Cardoso, J. M. D. O., de Brito, R. C. F., Aguiar‐Soares, R. D. D. O., Roatt, B. M., Vieira, P. M. D. A., & Reis, A. B. (2023) · Vaccines · doi:10.3390/vaccines11020395 · Cited by 7
Pal, S., Slepenkin, A., Felgner, J. H., Davies, D. H., Felgner, P. L., & de la Maza, L. M. (2023) · Pathogens · doi:10.3390/pathogens12070863 · Cited by 7
“Currently, we do not know if these differences between adjuvanticity and reactogenicity are qualitatively or quantitatively different [46,86].”
BackgroundLi, T., Xue, W., Zhang, S., Wang, H., Lan, M., Zhang, L., Lin, M., Zhou, M., Dong, Y., Zeng, Y., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01529-y · Cited by 10
Neeland, M. R., Shi, W., Collignon, C., Meeusen, E. N. T., Didierlaurent, A. M., & de Veer, M. J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13088 · Cited by 5
Self-citationHaseda, Y., Munakata, L., Kimura, C., Kinugasa‐Katayama, Y., Mori, Y., Suzuki, R., & Aoshi, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254628 · Cited by 6
Coccia, M., Burny, W., Demoitié, M., Gillard, P. H., van den Berg, R. A., & der Most, R. G. V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276505 · Cited by 6
Oxman, M. N., & Harbecke, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-44348-5_24 · Cited by 5
Galgani, I., Annaratone, M., Casula, D., Maro, G. D., Janssens, M., Tasciotti, A., Schwarz, T. F., Ferguson, M., & Arora, A. K. (2022) · Respiratory Research · doi:10.1186/s12931-022-02019-4 · Cited by 5
“After the single placebo injection, frequencies of individual solicited AEs, apart from fever, were generally lower than after each vaccine dose, which may be related to more intense activation of the innate immune response by AS-adjuvanted vaccines [16, 26].”
BackgroundSynthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy
Cuzzubbo, S., Roch, B., Darrasse-Jèze, G., Hosten, B., Leclercq, M., Vignal, N., Banissi, C., Tartour, É., & Carpentier, A. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314975 · Cited by 5
Segal, L. M., Thacker, K., Fochesato, M., Giordano, G., Garçon, N., & Destexhe, É. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2017.03.015 · Cited by 5
Self-citationNguyen, Q. T., Kim, E., Yang, J., Lee, C., Ha, D. H., Lee, C. G., Lee, Y. R., & Poo, H. (2020) · Vaccines · doi:10.3390/vaccines8020306 · Cited by 6
“The AS04 adjuvant composed of MPL and alum has been used in licensed vaccines for human papillomavirus and hepatitis B virus [43,44].”
MethodMarín, C., Moreno, F. N. R., Vallecillo, M. F. S., Pascual, M. M., Dho, N. D., Allemandi, D. A., Palma, S. D., Pistoresi-Palencia, M. C., Crespo, M. I., Gomez, C. G., et al. (2024) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2024.102749 · Cited by 4
Herpes zoster infection in patients with inflammatory bowel disease
Kim, D., & Kang, S. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.342 · Cited by 6
“Shingrix uses a VZV glycoprotein E antigen combined with an adjuvant system (AS01B) to elicit a strong immune response, even in immunocompromised individuals [52,53].”
Metadata
- Authors
- Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., Garçon, N., Van Mechelen, M., & Morel, S.
- Affiliations
- GlaxoSmithKline (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Centre National de la Recherche Scientifique (FR)
- GlaxoSmithKline Vaccines , 1330 Rixensart ,
- Corresponding author
- Collignon, Catherine
- Bourguignon, Patricia
- Wouters, Sandrine
- Fochesato, Michel
- Dendouga, Najoua
- Langlet, Christelle
- Morel, Sandra
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08
- Volume
- 193
- Issue
- 4
- Pages
- 1920-1930
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1942950379
- Cited by
- 266
- References
- 56
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 15 · 2023: 23 · 2022: 31 · 2021: 26 · 2020: 19 · 2019: 28 · 2018: 14 · 2017: 37 · 2016: 21 · 2015: 10 · 2014: 2
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- MPL, QS-21, dendritic cells, adaptive immune response, antigen presentation, MHC class II, monocytes, draining lymph nodes, cytokine production, innate immune activation, RTS,S malaria vaccine, varicella-zoster vaccine, T cell response, antibody response
- MeSH terms
- Adjuvants, Immunologic, Animals, Histocompatibility Antigens Class II, B-Lymphocytes, Dendritic Cells, Drug Combinations, Female, Humans, Lipid A, Lymphocyte Activation, Mice, Inbred C57BL, Monocytes, Saponins, Vaccination, Vaccines, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.